DrugPatentWatch Database Preview
Patent: 8,703,956
» See Plans and Pricing
Summary for Patent: 8,703,956
Title: | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid |
Abstract: | The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD.sub.2 at the CRTH2 receptor. |
Inventor(s): | Betancourt; Aimesther (Laval, CA), Lemieux; Marc (Laval, CA), Thibert; Roch (Laval, CA) |
Assignee: | Atopix Therapeutics Limited (Abingdon, Oxon, GB) |
Application Number: | 13/414,328 |
Patent Claims: | see list of patent claims |
Details for Patent 8,703,956
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS | 761122 | 001 | 2019-06-06 | Start Trial | Atopix Therapeutics Limited (Abingdon, Oxon, GB) | 2031-03-07 | RX | search | |
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | Atopix Therapeutics Limited (Abingdon, Oxon, GB) | 2031-03-07 | RX | Orphan | search |
Genentech | XOLAIR | omalizumab | VIAL | 103976 | 001 | 2003-06-20 | Start Trial | Atopix Therapeutics Limited (Abingdon, Oxon, GB) | 2031-03-07 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,703,956
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 201306560 | Start Trial |
World Intellectual Property Organization (WIPO) | 2012119841 | Start Trial |
United States of America | 2012282223 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |